The ROE as of November 2024 (TTM) for Arcutis Biotherapeutics, Inc. (ARQT) is -145.41%

According to Arcutis Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -145.41%. This represents a change of 171.32% compared to the average of -53.59% of the last 4 quarters.

Arcutis Biotherapeutics, Inc. (ARQT) Historical ROE (quarterly & annually)

How has ARQT ROE performed in the past?

The mean historical ROE of Arcutis Biotherapeutics, Inc. over the last ten years is -46.24%. The current -145.41% ROE has changed 214.46% with respect to the historical average. Over the past ten years (40 quarters), ARQT's ROE was at its highest in in the September 2019 quarter at 27.35%. The ROE was at its lowest in in the March 2018 quarter at -138.34%.

Arcutis Biotherapeutics, Inc. (ARQT) ROE by Quarter and Year

Discovering the peaks and valleys of Arcutis Biotherapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arcutis Biotherapeutics, Inc. (ARQT) Average ROE

How has ARQT ROE performed in the past?

The current ROE of Arcutis Biotherapeutics, Inc. (ARQT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Arcutis Biotherapeutics, Inc. (ARQT) ROE vs. Peers

How is ARQT’s ROE compared to its peers?

Arcutis Biotherapeutics, Inc.’s ROE is greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Icosavax, Inc. (-41.24%), greater than Mirum Pharmaceuticals, Inc. (-43.47%), greater than VectivBio Holding AG (-56.92%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), less than Spero Therapeutics, Inc. (20.70%), greater than Bolt Biotherapeutics, Inc. (-61.40%), less than Coherus BioSciences, Inc. (23.81%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Erasca, Inc. (-131.94%),

Build a custom stock screener for Arcutis Biotherapeutics, Inc. (ARQT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcutis Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcutis Biotherapeutics, Inc. (ARQT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcutis Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.